Targeted Delivery of NF-κB Inhibitor to Endothelial Cells
Author Information
Author(s): Ogawara Ken-ichi, Kułdo Joanna M, Oosterhuis Koen, Kroesen Bart-Jan, Rots Marianne G, Trautwein Christian, Kimura Toshikiro, Haisma Hidde J, Molema Grietje
Primary Institution: Okayama University, Japan
Hypothesis
Can RGD-PEG-modified adenovirus effectively deliver a dominant negative IκB gene to inhibit NF-κB signaling in endothelial cells?
Conclusion
The RGD-modified adenovirus successfully delivered the dnIκB gene, leading to the complete inhibition of TNF-α-induced up-regulation of several inflammatory markers in endothelial cells.
Supporting Evidence
- RGD modification shifted adenovirus entry from CAR-dependent to αvβ3 integrin-dependent.
- Transgene expression was confirmed by western blot analysis.
- TNF-α-induced up-regulation of inflammatory markers was completely abolished in dnIκB expressing cells.
- Over 80% of dnIκB expressing HUVECs remained viable after treatment.
Takeaway
Scientists created a special virus that can deliver a gene to stop inflammation in blood vessel cells, which could help treat diseases like arthritis.
Methodology
The study used RGD-PEG-modified adenovirus to deliver a dominant negative IκB gene to human umbilical vein endothelial cells and assessed the effects on gene expression using RT-PCR and flow cytometry.
Limitations
The study was conducted in vitro and may not fully represent in vivo conditions.
Participant Demographics
Human umbilical vein endothelial cells (HUVECs) were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website